Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial

• Main Authors: Torsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Malee Techapornroong, Niramon Leerattanapetch, Pacharee Kantipong, Chureeratana Bowonwatanuwong, Sukit Banchongkit, Virat Klinbuayaem, Sripetcharat Mekviwattanawong, Sireethorn Nimitvilai, Supunnee Jirajariyavej, Wisit Prasithsirikul, Warangkana Munsakul, Sorakij Bhakeecheep, Suchada Chaivooth, Praphan Phanuphak, David A. Cooper, Tanakorn Apornpong, Stephen J. Kerr, Sean Emery, Kiat Ruxrungtham
• Other Authors: The HIV Netherlands Australia Thailand Research Collaboration
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/40769
• Institution: Mahidol University

© 2016 Elsevier Ltd Background Thai patients with HIV have higher exposure to HIV protease inhibitors than do white people and dose reduction might be possible. We compared the efficacy of low-dose with standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai patients with HIV. Me...